p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells

Posted by rob on February 5, 2011 under Uncategorized | Comments are off for this article

In conclusion, our study points to p57Kip2 as a novel and precocious effector of BCR–ABL targeting drugs. (Source: Carcinogenesis)
More